Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rollover access study of rilpivirine with 2 NRTIs in HIV-1 infection
2010-021209-18Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rilpivirine in human immunodeficiency virus infection (HIV) and Human immunodeficiency virus infection type 1, sponsored by Janssen Pharmaceutical. Primary endpoint: Continued access to rilpivirine. Started Oct 2010; status: completed.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2010-021209-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021209-18.